Aethlon Medical To Initiate HIV Trials in India; Former Boston Scientific Executive To Manage Programs.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has retained Sunil Sawhney, the former Director of Boston Scientific India, and other regulatory advisors from Qualtran, LLC to manage clinical studies to treat patients infected with HIV (the AIDS virus) in India.

Aethlon CEO, James A. Joyce stated, "This is a tremendous market opportunity to demonstrate the effectiveness of our HIV-Hemopurifier." Joyce continued, "Our efforts in India reflect a strategic vision to complement our regulatory plans in the United States with global programs that help those infected with the AIDS virus and other infectious diseases." The Company stated site selection for the trials is under way, and that patient enrollment should begin in the coming months.

According to the Gates Foundation, 5.1 million individuals in India were infected with HIV in 2004, a ten-fold increase over the last decade. It is projected that the number of HIV-infected citizens in India could increase to 20-25 million by 2010. Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 16,000 employees and revenue of $5.6 billion in 2004. Qualtran, LLC is a clinical research organization focused on planning and managing human clinical trials in India.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopruifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.